Document is current
Any future updates will be listed below
-
Authors
Fini, Mehdi A.
Lanaspa, Miguel A.
Gaucher, Eric A.
Boutwell, Brian
Nakagawa, Takahiko
Wright, Richard M.
Sanchez-Lozada, Laura G.
Andrews, Peter
Stenmark, Kurt R.
Johnson, Richard J. https://orcid.org/0000-0003-3312-8193
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (HL014985)
National Institute of Diabetes and Digestive and Kidney Diseases (DK121496)
- License Information
-
More Information
Article History
Received: 23 February 2021
Accepted: 23 August 2021
First Online: 15 September 2021
Declarations
:
: Not applicable.
: The authors provide consent for publication and assure this manuscript is not under consideration elsewhere.
: RJJ, LGL, and ML have equity with Colorado Research Partners LLC that is developing inhibitors of fructose metabolism, and RJJ also has equity with XORTX Therapeutics developing xanthine oxidase inhibitors. Dr Johnson has consulted for Horizon Pharma. All other authors declare no competing interests.
